Semiconductor packaging and testing company Amkor Technology (NASDAQ:AMKR) reported Q1 CY2025 results exceeding the market’s revenue expectations , but sales fell by 3.2% year on year to $1.32 billion. On top of that, next quarter’s revenue guidance ($1.43 billion at the midpoint) was surprisingly good and 5.6% above what analysts were expecting. Its GAAP profit of $0.09 per share was in line with analysts’ consensus estimates. Is now the time to buy Amkor? Find out in our full research report. Amkor (AMKR) Q1 CY2025 Highlights: Revenue: $1.32 billion vs analyst estimates of $1.28 billion (3.2% year-on-year decline, 3.6% beat) EPS (GAAP): $0.09 vs analyst estimates of $0.09 (in line) Adjusted EBITDA: $197 million vs analyst estimates of $186 million (14.9% margin, 5.9% beat) Revenue Guidance for Q2 CY2025 is $1.43 billion at the midpoint, above analyst estimates of $1.35 billion EPS (GAAP) guidance for Q2 CY2025 is $0.15 at the midpoint, missing analyst estimates by 5.5% Operating Margin: 2.4%, down from 5.4% in the same quarter last year Free Cash Flow was -$55.75 million, down from $66.14 million in the same quarter last year Inventory Days Outstanding: 26, up from 20 in the previous quarter Market Capitalization: $4.34 billion Company Overview Operating through a largely Asian facility footprint, Amkor Technologies (NASDAQ:AMKR) provides outsourced packaging and testing for semiconductors. Sales Growth A company’s long-term sales performance is one signal of its overall quality. Even a bad business can shine for one or two quarters, but a top-tier one grows for years. Thankfully, Amkor’s 7.8% annualized revenue growth over the last five years was decent. Its growth was slightly above the average semiconductor company and shows its offerings resonate with customers. Semiconductors are a cyclical industry, and long-term investors should be prepared for periods of high growth followed by periods of revenue contractions.Amkor Quarterly Revenue Long-term growth is the most important, but short-term results matter for semiconductors because the rapid pace of technological innovation (Moore's Law) could make yesterday's hit product obsolete today. Amkor’s recent performance marks a sharp pivot from its five-year trend as its revenue has shown annualized declines of 5.1% over the last two years.Amkor Year-On-Year Revenue Growth This quarter, Amkor’s revenue fell by 3.2% year on year to $1.32 billion but beat Wall Street’s estimates by 3.6%. Despite the beat, the drop in sales could mean that the current downcycle is deepening. Company management is currently guiding for a 2.5% year-on-year decline in sales next quarter. Story Continues Looking further ahead, sell-side analysts expect revenue to grow 2.9% over the next 12 months. While this projection implies its newer products and services will spur better top-line performance, it is still below the sector average. Here at StockStory, we certainly understand the potential of thematic investing. Diverse winners from Microsoft (MSFT) to Alphabet (GOOG), Coca-Cola (KO) to Monster Beverage (MNST) could all have been identified as promising growth stories with a megatrend driving the growth. So, in that spirit, we’ve identified a relatively under-the-radar profitable growth stock benefiting from the rise of AI, available to you FREE via this link. Product Demand & Outstanding Inventory Days Inventory Outstanding (DIO) is an important metric for chipmakers, as it reflects a business’ capital intensity and the cyclical nature of semiconductor supply and demand. In a tight supply environment, inventories tend to be stable, allowing chipmakers to exert pricing power. Steadily increasing DIO can be a warning sign that demand is weak, and if inventories continue to rise, the company may have to downsize production. This quarter, Amkor’s DIO came in at 26, which is 5 days below its five-year average. These numbers show that despite the recent increase, there’s no indication of an excessive inventory buildup.Amkor Inventory Days Outstanding Key Takeaways from Amkor’s Q1 Results It was great to see Amkor’s revenue guidance for next quarter top analysts’ expectations. We were also glad its EPS outperformed Wall Street’s estimates. On the other hand, its inventory levels materially increased. Overall, we think this was a decent quarter with some key metrics above expectations. The stock traded up 2.2% to $17.86 immediately after reporting. Amkor may have had a good quarter, but does that mean you should invest right now? The latest quarter does matter, but not nearly as much as longer-term fundamentals and valuation, when deciding if the stock is a buy. We cover that in our actionable full research report which you can read here, it’s free. View Comments
Amkor (NASDAQ:AMKR) Beats Expectations in Strong Q1, Guides for Strong Sales Next Quarter
You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research.
Start Your Free Trial Now!Not sure where to invest today?
Kalkine’s latest research highlights three companies identified through in-depth analysis and market insights.
Explore these research reports to learn about companies currently being tracked by our analysts and make more informed investment decisions.
View 3 Research ReportsThis information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on ‘as is’ basis, using their API. The information and data provided on this page, as well as via the API, are not guaranteed to be real-time or accurate. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general informational purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine does not assume any responsibility for any trading losses you might incur as a result of using this information, data, or any analyst rating or recommendation provided. Kalkine will not accept any liability for any loss or damage resulting from reliance on the information, including but not limited to data, quotes, charts, analyst ratings, recommendations, and buy/sell signals sourced via the API.
Please be fully informed about the risks and costs associated with trading in the financial markets, as it is one of the riskiest forms of investment. Kalkine does not provide any warranties regarding the information on this page, including, without limitation, warranties of merchantability or fitness for a particular purpose or use.
Please wait processing your request...